Compare PDSB & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDSB | NNVC |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 37.9M |
| IPO Year | 2015 | 2008 |
| Metric | PDSB | NNVC |
|---|---|---|
| Price | $0.76 | $1.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 246.2K | ★ 359.1K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.16 | 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.85 |
| 52 Week High | $1.55 | $2.23 |
| Indicator | PDSB | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 40.90 |
| Support Level | $0.63 | $1.13 |
| Resistance Level | $0.76 | $1.47 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 76.46 | 7.37 |
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.